PRUDENTIAL FINANCIAL INC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 180 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2019. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRUDENTIAL FINANCIAL INC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$228,481
-54.5%
6,409
-41.1%
0.00%
-100.0%
Q2 2023$502,356
+91.2%
10,890
+66.2%
0.00%
Q1 2023$262,775
-24.5%
6,553
-21.9%
0.00%
-100.0%
Q3 2022$348,000
-82.2%
8,390
-74.4%
0.00%
-66.7%
Q2 2022$1,959,000
-55.7%
32,835
-46.1%
0.00%
-50.0%
Q1 2022$4,425,000
+837.5%
60,935
+985.2%
0.01%
+500.0%
Q4 2021$472,000
-74.7%
5,615
-72.9%
0.00%
-66.7%
Q3 2021$1,869,000
-78.7%
20,715
-77.5%
0.00%
-75.0%
Q2 2021$8,775,000
-43.5%
92,029
-32.6%
0.01%
-47.8%
Q1 2021$15,536,000
-23.4%
136,448
-6.9%
0.02%
-32.4%
Q4 2020$20,294,000
+77.8%
146,603
+5.6%
0.03%
+61.9%
Q3 2020$11,412,000
+605.3%
138,837
+571.4%
0.02%
+600.0%
Q2 2020$1,618,000
-48.9%
20,679
-71.0%
0.00%
-57.1%
Q1 2020$3,165,000
+233.2%
71,220
+220.1%
0.01%
+600.0%
Q4 2019$950,000
+193.2%
22,250
+335.4%
0.00%0.0%
Q2 2019$324,000
-6.1%
5,110
+2.6%
0.00%0.0%
Q1 2019$345,000
+3.3%
4,980
+13.7%
0.00%
Q3 2018$334,000
-0.9%
4,3800.0%0.00%
-100.0%
Q2 2018$337,000
+59.7%
4,380
+6.1%
0.00%
Q1 2018$211,000
-85.0%
4,130
-86.4%
0.00%
-100.0%
Q4 2017$1,407,000
+48.9%
30,334
+71.0%
0.00%
+100.0%
Q3 2017$945,000
+125.0%
17,740
+162.0%
0.00%0.0%
Q2 2017$420,000
+69.4%
6,770
+85.0%
0.00%
Q1 2017$248,000
+2.1%
3,660
+5.8%
0.00%
Q4 2016$243,000
-0.8%
3,460
+0.3%
0.00%
Q3 2016$245,000
-18.1%
3,450
-27.0%
0.00%
-100.0%
Q1 2016$299,000
-15.3%
4,724
+50.0%
0.00%0.0%
Q4 2015$353,000
+26.5%
3,150
+8.6%
0.00%0.0%
Q3 2015$279,000
+7.3%
2,900
+14.2%
0.00%
Q2 2015$260,0002,5400.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2019
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 519,119$40,605,0003.00%
First Light Asset Management, LLC 236,958$18,535,0002.16%
SECTOR GAMMA AS 108,734$8,505,0001.76%
Rock Springs Capital Management LP 646,841$50,596,0001.39%
Atika Capital Management LLC 79,000$6,180,0000.80%
Capital Impact Advisors, LLC 30,582$2,392,0000.80%
FEDERATED HERMES, INC. 4,080,359$319,166,0000.79%
Rhenman & Partners Asset Management AB 61,500$4,811,0000.52%
Ikarian Capital, LLC 73,500$5,749,0000.46%
Capital International, Inc./CA/ 477,858$37,378,0000.46%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders